Related Experiment Video
Updated: Aug 5, 2025
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Plasma Lipoprotein-Associated Phospholipase A2 Affects Cognitive Impairment in Patients with Cerebral Microbleeds
Lu Liu1, Xiaojiu Zhang1,2, Nan Jiang3
1Department of Neurology, Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, People's Republic of China.
Purpose:
The plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker of cerebral microbleeds (CMBs) and may be related to the occurrence, development, and prognosis of cognitive impairment. The present study aimed to investigate the impact of plasma Lp-PLA2 level on the cognitive impairment in patients with CMBs.
Methods:
In this study, 213 patients with CMBs confirmed by 3.0 T brain magnetic resonance imaging (MRI) were analyzed. Lp-PLA2 levels were determined by magnetic particle chemiluminescence immunoassay technology, and cognitive function was assessed using the Montreal Cognitive Assessment Scale (MoCA). The cognitive functions of patients with CMBs were divided into three groups according to the MoCA scale, including normal cognition (NC), mild cognitive impairment (MCI), and moderate-severe cognitive impairment (MSCI). Clinical, laboratory and radiological data of the three groups were analysed. The relationship between plasma Lp-PLA2 and MoCA score in patients with CMBs was investigated through rank correlation analysis and multivariate regression analysis, and receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of Lp-PLA2.
Results:
CMBs were detected in 213 (30.2%) of 705 patients who underwent 3.0 T MRI. Multiple comparisons showed that plasma Lp-PLA2 in patients with CMBs with normal cognitive scores was significantly lower than that in the other two groups with cognitive impairment (p < 0.05). In the single factor correlation analysis, high level of plasma Lp-PLA2 was negatively correlated with the decrease of MoCA score in patients with CMBs (r =-0.389, p < 0.01). Multivariate regression analysis showed that high plasma Lp-PLA2 was an independent risk factor for a low MoCA score in patients with CMBs (odds ratio [OR]=1.014; 95% confidence interval [CI], 1.002-1.026; p=0.025).
Conclusion:
A high level of plasma Lp-PLA2 is positively correlated with the generation of cognitive impairment in patients with CMBs and negatively correlated with the degree of impairment. Plasma Lp-PLA2 is an important indicator of cognitive impairment in patients with CMBs and may provide a therapeutic target for preventing CMB-induced cognitive impairment.
Insights
High levels of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) are linked to cognitive impairment in patients with cerebral microbleeds (CMBs). This inflammatory biomarker may indicate a higher risk and severity of cognitive decline in these patients.
Area of Science:
- Neuroscience
- Biomarkers
- Inflammation
Background:
- Cerebral microbleeds (CMBs) are associated with cognitive impairment.
- Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker.
- Lp-PLA2 may play a role in the development and prognosis of cognitive impairment.
Purpose of the Study:
- To investigate the impact of plasma Lp-PLA2 levels on cognitive impairment in patients with CMBs.
- To determine if Lp-PLA2 is an independent risk factor for cognitive decline in CMB patients.
Main Methods:
- 213 patients with CMBs (confirmed by 3.0 T MRI) were analyzed.
- Plasma Lp-PLA2 levels were measured using chemiluminescence immunoassay.
- Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale.
Main Results:
- Plasma Lp-PLA2 levels were significantly higher in patients with cognitive impairment (MCI, MSCI) compared to those with normal cognition (NC).
- High Lp-PLA2 levels showed a negative correlation with MoCA scores (r=-0.389, p<0.01).
- Elevated plasma Lp-PLA2 was identified as an independent risk factor for low MoCA scores in CMB patients (OR=1.014, p=0.025).
Conclusions:
- Elevated plasma Lp-PLA2 levels are associated with cognitive impairment in patients with CMBs.
- Lp-PLA2 is a potential indicator for cognitive impairment in CMB patients.
- Plasma Lp-PLA2 may serve as a therapeutic target for preventing CMB-induced cognitive impairment.
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...